5[1]Latscha BD, Herbflin A. Long-term dialysis and cellular immunity: a critical survey .Kidney Int, 1993,43(Suppl 41):135
6[2]Huraib S, FRCP(C), FACP, et al. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kid Dis, 1997,866
7[3]Pfaffl W, Gross HJ, Neumeier D, et al. Lymphocyte susbets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. In: Koch KM, Kuhn K,Nonnast-Daniel B, et al. Treatment of renal anemia with recombinant human erythropoietin. Contrib Nephrol, Basel Karger, 1998. 195
8[4]Collart FE, Dratwa M, Wittek M, et al. Effect of recombinant human erythropoitin on T lymphocyte subsets in hemodialysis patients. Asaio Trans, 1990, 36:219
9[5]Bartunkova J, Sulkova S, Cebecauer M. The effect of recombinant erythropoirtin on candidicidal activity of polymorphonuclear leukocytrs in hemodialyzed patients. Cas Lek Cesk, 1995, 134(23):756
10Koyama T, Temma K, Akera T. Reperfusion-induced contracture develops with a decreasing [Ca2+]i in single heart cells[J]. Am J Physiol, 1991, 261(4 Pt 2): H1115-H1122.
4National Kidney Foundation. K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification, and stratifica- tion. Am J Kidney Dis, 2002, 39(2 Suppl 1):S1-S266.
5Ng D P, Nurbaya S, Ye S H, et al. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int, 2008, 74(4):521-527.
